Early Marker and Etiologic Studies in the PLCO Trial

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by:
National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier:
NCT00339495
First received: June 19, 2006
Last updated: March 14, 2014
Last verified: June 2013

June 19, 2006
March 14, 2014
July 1997
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00339495 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Early Marker and Etiologic Studies in the PLCO Trial
Early Marker and Etiologic Studies in the PLCO Trial

The Division of Cancer Prevention and Control (DCPC), under extramural contracts to 10 U.S. clinical centers, is evaluating the effectiveness of screening for prostate, lung, colorectal and ovarian cancer (The PLCO Trial). The NCI Executive Committee approved the expansion of the PLCO Trial to collect additional materials and to conduct additional studies. About 74,000 men and 74,000 women, aged 55-74 years, are being randomized on a 50/50 basis into screening or usual care arms. Additional blood will be collected from screened subjects and saliva for buccal cells from control subjects. Pathologic tissues will be obtained for cases that develop cancer or selected related diseases (e.g., colon polyps, benign prostatic hyperplasia). Additional questionnaire-based risk information will also be collected. Genetic, biochemical and questionnaire-based risk information will be related to the development of cancer and other diseases in this population. Volunteers who provide samples for these studies will not routinely receive their individual results from the Additional Investigation. Subjects requesting such information, however, will be provided their test results. This protocol Review Application is for the collaboration of intramural scientists in the Division of Cancer Epidemiology and Genetics (DCEG) in the Additional Studies.

The Division of Cancer Prevention and Control (DCP, formerly DCPC), under extramural contracts to 10 U.S. clinical centers, is evaluating the effectiveness of screening for prostate, lung, colorectal and ovarian cancer (The PLCO Trial). In 1996 the NCI Executive Committee approved the expansion of the PLCO Trial to collect additional materials and to conduct additional studies. About 74,000 men and 74,000 women, aged 55-74 years, have been randomized on a 50/50 basis into screening or usual care arms. Additional blood is collected from screened subjects and saliva for buccal cells from control subjects. Pathologic tissues are obtained for cases that develop cancer or selected related diseases (e.g., colon polyps, benign prostatic hyperplasia). Additional questionnaire-based risk and disease-related information is also collected, with confirmation of disease status from medical records. Genetic, biochemical and questionnaire-based risk information will be related to the development of cancer and other diseases in this population. Volunteers who provide samples for these studies will not routinely receive their individual results from the Additional Investigation. Subjects requesting such information, however, will be provided with the research results. In 2009 the NCI Executive Committee approved the Extended Follow-up of subjects beyond the original 13-year follow-up period. Participants will be reconsented for the release of records to a single NCI-Designated Central Data Collection Center (CDCC), which will administer the annual mailings containing the annual study update questionnaire and a brief (1-2 page) risk factor questionnaire. Individuals who do not consent to release their identifiers to the CDCC will be followed up passively through linkage to state cancer registries and the National Death Index.

This protocol Review Application is for (1) the collaboration of intramural scientists in the Division of Cancer Epidemiology and Genetics (DCEG) in the Additional Studies and (2) the coordination, in collaboration with DCP, of the Extended Follow-up.

Observational
Not Provided
Not Provided
Not Provided
Not Provided
Not Provided
Cancer
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
156000
Not Provided
Not Provided
  • INCLUSION CRITERIA:

Men and women aged 55-74 years.

Subjects who do not have a prior history of PLCO tumors and have not undergone routine screening.

Both
55 Years to 74 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00339495
999997041, OH97-C-N041
Not Provided
Not Provided
National Cancer Institute (NCI)
Not Provided
Principal Investigator: Robert N Hoover, M.D. National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
June 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP